Eur Respir J.: Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa.

By Erica Lessem | 09 May, 2018

Dear all,
Please see this article which highlights the importance of availability of
delamanid based on use in a large cohort of patients with
difficult-to-treat MDR-TB.

Eur Respir J. <> 2018 May 3.
pii: 1800017. doi: 10.1183/13993003.00017-2018. [Epub ahead of print]

*Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study
from South Africa.*

Mohr E
1, Hughes J
1, Reuter A
1, Trivino Duran L
1, Ferlazzo G
2, Daniels J
1, De Avezedo V
3, Kock Y
4, Jane Steele S
5, Shroufi A
5, Ade S
6, Alikhanova N
7, Benedetti G
8, Edwards J
8,9, Cox H
10, Furin J
11, Isaakidis P

*Author information <>*



Experience with delamanid (Dlm) is limited, particularly among HIV-positive
individuals. We describe early efficacy and safety from a programmatic
setting in South Africa.


This was a retrospective cohort study of patients receiving Dlm-containing
treatment regimens between November 2015 and August 2017. Twelve-month
interim outcomes, sputum culture conversion (SCC) by months-2 and 6,
serious adverse events (SAEs), and QTcF data were reported.


Overall, 103 patients initiated Dlm; 79(77%) were HIV-positive. The main
indication for Dlm was intolerance to second-line anti-TB drugs (n=58,
56%). Forty-six patients had 12-months of follow-up; 28(61%) had a
favorable outcome (cure, treatment completion, or culture negativity).
Fifty-seven patients had positive cultures at Dlm initiation; 16/31(52%)
and 25/31(81%) had SCC within 2 and 6-months, respectively. There were 67
SAEs reported in 29(28%) patients. There were four instances of QTcF
prolongation >500 ms in 2(2%) patients, leading to permanent
discontinuation in one case, however no cardiac arrhythmias occurred.


This large cohort of difficult-to-treat patients receiving Dlm for
rifampicin-resistant tuberculosis treatment in a programmatic setting with
high HIV prevalence had favorable early treatment response and tolerated
treatment well. Dlm should remain available, particularly for those that
cannot be treated with conventional regimens and/or with limited treatment

Copyright ©ERS 2018.




10.1183/13993003.00017-2018 <>